Inhibrx Biosciences (INBX) Change in Account Payables (2023 - 2025)

Inhibrx Biosciences (INBX) has reported Change in Account Payables for 3 consecutive years, with -$829000.0 the latest figure, recorded in Q4 2025.

• In Q4 2025, Change in Account Payables rose 73.42% year-over-year to -$829000.0; the TTM figure through Dec 2025 stood at -$3.3 million (down 118.44% YoY), while the FY2025 annual figure was -$3.3 million, down 118.44% from the prior year.
• Change in Account Payables advanced to -$829000.0 in Q4 2025 per INBX's latest filing, from -$1.5 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $17.4 million in Q2 2024 and bottomed at -$3.1 million in Q4 2024.
• Historically, Change in Account Payables has averaged $1.6 million across 3 years, with a median of -$525000.0 in 2024.
• On a YoY basis, Change in Account Payables climbed as much as 73.42% in 2025 and fell as far as 237.56% in 2025.
• Inhibrx Biosciences' Change in Account Payables stood at $2.9 million in 2023, then plunged by 207.18% to -$3.1 million in 2024, then jumped by 73.42% to -$829000.0 in 2025.
• Business Quant data shows INBX's Change in Account Payables at -$829000.0 in Q4 2025, -$1.5 million in Q3 2025, and -$600000.0 in Q2 2025.